Pfizer Inc (PFE) Files Form 4 Insider Selling : Frank A Damelio Sells 100,000 Shares

Pfizer Inc (PFE): Frank A Damelio , Executive Vice President of Pfizer Inc sold 100,000 shares on May 26, 2016. The Insider selling transaction was reported by the company on May 27, 2016 to the Securities and Exchange Commission. The shares were sold at $34.49 per share for a total value of $3,449,115.25 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 26, 2016, Loretta V Cangialosi (Sr. Vice President, Controller) sold 86,000 shares at $33.97 per share price.On May 12, 2016, Laurie J Olson (Executive Vice President) sold 4,700 shares at $33.50 per share price.Also, On May 11, 2016, John D Young (Group President) sold 41,700 shares at $33.54 per share price.On May 11, 2016, Frank A Damelio (Executive Vice President) sold 192,000 shares at $33.66 per share price.

Pfizer: On Wednesday, May 25, 2016 heightened volatility was witnessed in Pfizer which led to swings in the share price. The shares opened for trading at $34.12 and hit $34.4 on the upside , eventually ending the session at $34.35, with a gain of 0.73% or 0.25 points. The heightened volatility saw the trading volume jump to 2,10,36,679 shares. The 52-week high of the share price is $36.46 and the company has a market cap of $208,328 M . The 52-week low of the share price is at $28.25.

Pfizer Money Flow Index Chart

Company has been under the radar of several Street Analysts.Pfizer is Initiated by Berenberg to Hold and the brokerage firm has set the Price Target at $38. The Rating was issued on May 12, 2016.Pfizer is Reiterated by UBS to Buy and the brokerage firm has raised the Price Target to $ 38 from a previous price target of $36 .The Rating was issued on May 4, 2016.Pfizer is Resumed by Goldman to Neutral and the brokerage firm has set the Price Target at $35. The Rating was issued on Apr 18, 2016.Pfizer is Resumed by JP Morgan to Overweight and the brokerage firm has set the Price Target at $38. The Rating was issued on Apr 7, 2016.Pfizer is Resumed by Morgan Stanley to Equal-Weight and the brokerage firm has set the Price Target at $35. The Rating was issued on Apr 7, 2016.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.